Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

1. Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V

Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Naldemin (opioidinduzierte Obstipation) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 August 2020). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A20-45 Naldemedine (opioid-induced constipation) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-45 Version 1.0 Naldemedine (opioid-induced constipation) 13 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Naldemedine (opioid-induced constipation) – Benefit assessment according to §35a Social

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Naldemedine for treating opioid-induced constipation

Naldemedine for treating opioid-induced constipation Naldemedine for treating opioid-induced constipation T echnology appraisal guidance Published: 30 September 2020 www.nice.org.uk/guidance/ta651 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naldemedine for treating opioid-induced constipation (TA651) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about naldemedine 5 Marketing authorisation indication 5 Dosage in the marketing authorisation 5 Price 5 3

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Interventions for preventing postpartum constipation. Full Text available with Trip Pro

Interventions for preventing postpartum constipation. Postpartum constipation, with symptoms, such as pain or discomfort, straining, and hard stool, is a common condition affecting mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones, and haematinics used in pregnancy can increase the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake are usually encouraged. Although laxatives are commonly used in relieving constipation (...) , the effectiveness and safety of available interventions for preventing postpartum constipation should be ascertained. This is an update of a review first published in 2015.To evaluate the effectiveness and safety of interventions for preventing postpartum constipation.We searched Cochrane Pregnancy and Childbirth's Trials Register, and two trials registers ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (7 October 2019), and screened reference lists of retrieved trials.We

2020 Cochrane

4. Randomised controlled trial of a comprehensive protocol for preventing constipation following total hip arthroplasty

Randomised controlled trial of a comprehensive protocol for preventing constipation following total hip arthroplasty Randomised controlled trial of a comprehensive protocol for preventing constipation following total hip arthroplasty - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Nurs Actions . 2020 Aug;29(15-16):2863-2871. doi: 10.1111/jocn.15299. Epub 2020 May 26. Randomised controlled trial of a comprehensive protocol for preventing constipation following total hip arthroplasty , , , , Affiliations Expand Affiliations 1 Department of Orthopedic Surgery, Luoyang Orthopedic Hospital of Henan Province. Orthopedic Hospital of Henan Province, Luoyang, China. 2 Zhejiang Chinese

2020 EvidenceUpdates

5. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis

Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Pain Med Actions . 2020 Jun 3;pnaa152. doi: 10.1093/pm/pnaa152. Online ahead of print. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis , , , , Affiliations Expand Affiliations 1 Department of Gastroenterology, The Second Affiliated

2020 EvidenceUpdates

6. Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC)

Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC) Published 13 April 2020 1 SMC2242 naldemedine 200 micrograms film-coated tablets (Rizmoic®) Shionogi BV 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission naldemedine (Rizmoic ® ) is accepted (...) for use within NHSScotland. Indication under review: For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the treatment of opioid induced constipation (OIC) in adult

2020 Scottish Medicines Consortium

7. Lactitol (Pizensy) - To treat chronic idiopathic constipation (CIC) in adults

Lactitol (Pizensy) - To treat chronic idiopathic constipation (CIC) in adults Drug Approval Package: PIZENSY PIZENSY " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: PIZENSY Company: Braintree Laboratories, Inc. Application Number: 211281 Approval Date: 02/12/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

8. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History (...) be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Gastroenterol Actions , 115 (2), 281-293 Feb 2020 Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) , , Affiliations Expand Affiliations 1 Division

2020 EvidenceUpdates

9. Palliative care - constipation: Scenario: End of life care

Palliative care - constipation: Scenario: End of life care Scenario: End of life care | Management | Palliative care - constipation | CKS | NICE Search CKS… Menu Scenario: End of life care Palliative care - constipation: Scenario: End of life care Last revised in October 2016 Scenario: End of life care End of life care It can often be difficult to be certain that a person is dying, but it is essential to recognize the signs of dying in order to appropriately care for people at the end of life

2020 NICE Clinical Knowledge Summaries

10. Palliative care - constipation: Scenario: Assessment

Palliative care - constipation: Scenario: Assessment Scenario: Assessment | Management | Palliative care - constipation | CKS | NICE Search CKS… Menu Scenario: Assessment Palliative care - constipation: Scenario: Assessment Last revised in October 2016 Scenario: Assessment From age 16 years onwards. How should I assess a person with constipation in palliative care? Attempt to diagnose the cause of constipation — this will include an abdominal and rectal examination (avoid rectal examination (...) in people receiving chemotherapy). Exclude bowel obstruction. Features which suggest obstruction include: Known presence of intra-abdominal tumour. Absence of passage of flatus per rectum. Nausea and vomiting. Colicky, abdominal pain. Abdominal distension. Abdominal tenderness without guarding or rebound. Active, tinkling bowel sounds; or quiet or absent bowel sounds (a late sign). Identify when the constipation first became a problem (if constipation pre-dates the illness requiring palliative care

2020 NICE Clinical Knowledge Summaries

11. Palliative care - constipation: Scenario: Management

Palliative care - constipation: Scenario: Management Scenario: Management | Management | Palliative care - constipation | CKS | NICE Search CKS… Menu Scenario: Management Palliative care - constipation: Scenario: Management Last revised in October 2016 Scenario: Management From age 16 years onwards. How should I prevent constipation when prescribing a constipating drug? When introducing an opioid (or any other constipating drug), advise the person of the risks of constipation, and prescribe (...) a stimulant laxative (such as senna or dantron-containing laxative) at the time of first prescription, rather than waiting until constipation is established. Aim for a regular bowel movement, without straining, every 1 – 3 days. Dose of senna: If not constipated start with 15 mg at bedtime. If there is no bowel movement after 24 – 48 hours, increase to 15 mg at bedtime and 15 mg each morning. If already constipated, start with 15 mg at bedtime and 15 mg each morning. If there is no response after 24 – 48

2020 NICE Clinical Knowledge Summaries

12. Palliative care - constipation: How should I prevent adverse effects of rectal laxatives?

Palliative care - constipation: How should I prevent adverse effects of rectal laxatives? Preventing adverse effects of rectal laxatives | Prescribing information | Palliative care - constipation | CKS | NICE Search CKS… Menu Preventing adverse effects of rectal laxatives Palliative care - constipation: How should I prevent adverse effects of rectal laxatives? Last revised in October 2016 How should I prevent adverse effects of rectal laxatives? Suppositories: Must be placed alongside

2020 NICE Clinical Knowledge Summaries

13. Palliative care - constipation: How long is it before different laxative preparations take effect?

Palliative care - constipation: How long is it before different laxative preparations take effect? Time to wait for laxative effect | Prescribing information | Palliative care - constipation | CKS | NICE Search CKS… Menu Time to wait for laxative effect Palliative care - constipation: How long is it before different laxative preparations take effect? Last revised in October 2016 How long is it before different laxative preparations take effect? For information on times for different laxative

2020 NICE Clinical Knowledge Summaries

14. Palliative care - constipation: How do laxatives work?

Palliative care - constipation: How do laxatives work? How laxatives work | Prescribing information | Palliative care - constipation | CKS | NICE Search CKS… Menu How laxatives work Palliative care - constipation: How do laxatives work? Last revised in October 2016 How do laxatives work? Bulk-forming laxatives (ispaghula husk, methylcellulose, and sterculia) act by retaining fluid within the stool and increasing faecal mass, leading to stimulation of peristalsis. They also have stool-softening

2020 NICE Clinical Knowledge Summaries

15. Palliative care - constipation: Diagnosis of constipation in palliative care

Palliative care - constipation: Diagnosis of constipation in palliative care Diagnosis | Diagnosis | Palliative care - constipation | CKS | NICE Search CKS… Menu Diagnosis Palliative care - constipation: Diagnosis of constipation in palliative care Last revised in October 2016 Diagnosis of constipation in palliative care Suspect constipation when: Stools are hard, uncomfortable, or difficult to pass, and are less frequent than usual; or the person has a sense of incomplete evacuation after

2020 NICE Clinical Knowledge Summaries

16. Palliative care - constipation: Adverse effects of oral laxatives

Palliative care - constipation: Adverse effects of oral laxatives Adverse effects of oral laxatives | Prescribing information | Palliative care - constipation | CKS | NICE Search CKS… Menu Adverse effects of oral laxatives Palliative care - constipation: Adverse effects of oral laxatives Last revised in October 2016 Adverse effects of oral laxatives Most adverse effects can be avoided or reduced by increasing the dose of oral laxatives gradually. Advise people to start at the lowest dose

2020 NICE Clinical Knowledge Summaries

17. Palliative care - constipation

Palliative care - constipation Palliative care - constipation | Topics A to Z | CKS | NICE Search CKS… Menu Palliative care - constipation Palliative care - constipation Last revised in October 2016 Constipation is defecation that is unsatisfactory because of infrequent stools, difficult stool passage, or seemingly incomplete defecation. Diagnosis Management Prescribing information Background information Palliative care - constipation: Summary Constipation is defecation that is unsatisfactory (...) because of infrequent stools, difficult stool passage, or seemingly incomplete defecation. Stools are often dry and hard, and may be abnormally large or abnormally small. About 80% of people with cancer will require treatment with laxatives at some time. People receiving palliative care have multiple causes of constipation, such as: Drugs, for example, opioid analgesics, antimuscarinic drugs, antacids. Secondary effects of disease, for example, dehydration, inadequate dietary fibre, inactivity

2020 NICE Clinical Knowledge Summaries

18. Constipation: When should I suspect constipation?

Constipation: When should I suspect constipation? Diagnosis | Diagnosis | Constipation | CKS | NICE Search CKS… Menu Diagnosis Constipation: When should I suspect constipation? Last revised in May 2020 When should I suspect constipation? Suspect a diagnosis of constipation if an adult presents with defecation which is unsatisfactory because of infrequent stools, difficulty passing stools, or a sensation of incomplete emptying. Typically, bowel movements occurring less than three times a week (...) may be regarded as constipation. There may be daily bowel movements but associated symptoms such as excessive straining. Additional symptoms may include lower abdominal pain or discomfort, distension, or bloating. In reality, constipation is often defined as passage of stools less frequently than the person's normal pattern. Consider a diagnosis of constipation in the elderly if there are non-specific symptoms, such as: Confusion or delirium, functional decline. Nausea or loss of appetite

2020 NICE Clinical Knowledge Summaries

19. Constipation: How should I assess an adult with constipation?

Constipation: How should I assess an adult with constipation? Assessment | Diagnosis | Constipation | CKS | NICE Search CKS… Menu Assessment Constipation: How should I assess an adult with constipation? Last revised in May 2020 How should I assess an adult with constipation? If a diagnosis of constipation is , ask about: Any red flag symptoms or signs that may suggest a serious underlying cause, such as colorectal cancer. See the CKS topic on for more information. What the person means (...) by 'constipation' and their normal pattern of defecation. The person's perception of a normal bowel habit may influence the diagnosis of constipation. The duration of constipation, and the frequency and consistency of stools, such as hard/small (pebble-like) or large stools (for example, do they block the toilet); any nocturnal symptoms. Consider the use of the to provide an objective record of the person's stool form. Associated symptoms such as rectal discomfort, excessive straining, feeling of incomplete

2020 NICE Clinical Knowledge Summaries

20. Constipation: Contraindications and cautions

Constipation: Contraindications and cautions Contraindications and cautions | Prescribing information | Constipation | CKS | NICE Search CKS… Menu Contraindications and cautions Constipation: Contraindications and cautions Last revised in May 2020 Contraindications and cautions Do not prescribe laxatives if there is suspected: Intestinal obstruction or perforation. Paralytic ileus. Colonic atony or faecal impaction (bulk-forming laxatives). Crohn's disease or ulcerative colitis. Toxic

2020 NICE Clinical Knowledge Summaries